Announcement • Jun 05
MindBio Therapeutics Corp. Launches Intox AI for Validation and Testing MindBio Therapeutics Corp. has launched its lead commercial software Intox AI for validation and testing. MindBio’s enterprise solution for intoxication and fatigue detection, Intox AI enables new analytical capabilities to detect Cocaine, Cannabis, Alcohol, Psychedelics, Narcotic use and human fatigue from voice. Intox AI is a category changer in drug use and fatigue detection in high-risk industries where sobriety and alertness is an essential health and safety requirement that saves lives. The technology will be deployed to the Edge AI Kiosks that are due for initial prototype manufacturing completion shortly. The Company is targeting industries for commercialisation that have pressure to scale up drug and alcohol testing and where testing is mandated by regulators, such as the mining industry, aviation and construction, heavy transport, law enforcement and where high volume testing at scale for a variety of drugs and alcohol and human fatigue presents major challenges for management. The current systems for drug and alcohol testing involve a mouth swab test and breathalyser. These tests are time consuming, costly on a per test basis, unhygienic and environmentally harmful due to the quantity of plastic use and waste disposal. MindBio’s Voice AI solution aims to provide quick scanning for intoxication and removes these problems from legacy drug testing procedures. MindBio’s solution aims to deliver enhanced efficiency and testing at scale, not possible with current systems. The Company is on track to deliver its first prototype testing kiosks shortly and is delighted the core software is ready for testing and validation. New Risk • Jun 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.6m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-AU$1.3m). Shareholders have been substantially diluted in the past year (433% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$4.73m market cap, or US$3.42m). Announcement • May 11
MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AI MindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement. 
